The Translational medicinal and biological chemistry group is focused on the design, synthesis, biological evaluation, study and further optimization of pharmacokinetic properties of structurally diverse chemical entities for drug discovery. The efforts of our group are focused on the discovery of innovative drugs with novel mechanism of action as disease-modifying agents for unmet severe pathologies such as neurodegenerative and infectious diseases. Our group applies medicinal chemistry programs combining classical and computational medicinal chemistry.
https://www.youtube.com/embed/bAtlkpHs2FcFor the design of our drugs (mainly small heterocyclic molecules with MW<500), different strategies will be used. These include computer-aided drug design, multifunctional compounds bearing different pharmacophore moieties in the same molecule to interact with different targets, and improving ADME properties of the candidates, among others. The group has developed an in-house chemical library (called MBC library) containing over 3000 compounds with privileged scaffolds which is continuously growing and extensively used in our directed biological and computational screening programs.
Our research is applied with a high content of translational research. The group's research programs are designed from the early stages of drug discovery to proof of efficacy in representative animal models. Scientific collaborations and technology transfer to companies in the pharmaceutical sector are key tasks in achieving our goals.
We are members of different national and international excellent research networks and infrastructures such as EU-OPENSCREEN (https://www.eu-openscreen.eu/) and CIBERNED (https://ciberned.es/). Furthermore, we have found two spin-offs focused on drug discovery and development: AnkarPharma and Molefy Pharma (https://molefypharma.com/en/home/).
